
ICAD Inc. has made significant strides in expanding its executive leadership team. The company has appointed new members to its leadership team, bringing in fresh perspectives and expertise.
This strategic move is expected to drive innovation and growth for the company. ICAD Inc. aims to leverage its expanded leadership team to further develop its AI solutions.
With a focus on delivering cutting-edge AI technology, ICAD Inc. continues to push the boundaries of what is possible. The company's commitment to innovation is evident in its ongoing efforts to improve its AI solutions.
ICAD Inc.'s AI solutions are designed to meet the evolving needs of its clients. By staying ahead of the curve, the company is well-positioned to capitalize on emerging trends and opportunities.
Financial Information
ICAD, Inc. reported a revenue of $19.61 million in 2024, a 13.22% increase from the previous year.
This significant growth is a testament to the company's ability to adapt and thrive in a competitive market.
Financial Performance
iCAD, Inc.'s revenue in 2024 was $19.61 million, a 13.22% increase from the previous year.
The company's revenue growth is a notable achievement, especially considering the challenges many businesses face in a competitive market.
In 2024, iCAD, Inc.'s losses totaled -$5.62 million, a 15.9% increase from the previous year's losses.
This increase in losses is a significant factor to consider when evaluating the company's overall financial performance.
The revenue increase of 13.22% in 2024 is a substantial improvement from the previous year's revenue of $17.32 million.
iCAD, Inc.'s financial performance in 2024 highlights the importance of monitoring revenue and loss trends over time.
Related reading: 22 Dólares Em Reais
Nasdaq:ICAD
iCAD, Inc. (NASDAQ:ICAD) is a company that's making waves in the medical industry with its AI-powered solutions for cancer detection, breast density assessment, and risk analysis.
Their technology is so advanced that it's being used to provide radiologists with a streamlined AI-driven pathway from screening to diagnosis.
iCAD has formed a reseller partnership with Koios Medical to offer an AI-powered breast cancer detection suite that integrates iCAD's ProFound AI for mammography with Koios SmartUltrasound.
Recommended read: Anomaly Detection Datadog
This collaboration aims to improve accuracy, efficiency, and patient outcomes, especially for patients with dense breast tissue.
The AI-powered breast cancer detection suite uses Koios SmartUltrasound to advance cancer detection in ultrasound exams, enabling faster diagnoses and reducing unnecessary procedures.
Here are some key stats about iCAD's partnership with Koios Medical:
- Integration of iCAD's ProFound AI for mammography with Koios SmartUltrasound
- Streamlined AI-driven pathway from screening to diagnosis
- Improved accuracy, efficiency, and patient outcomes
- Especially beneficial for patients with dense breast tissue
Partnerships and Deals
iCAD Inc. has formed strategic partnerships to deliver its AI-powered cancer detection solutions. The company partnered with RamSoft to deliver ProFound AI-Powered Mammography Solutions Across North America.
The partnership aims to enhance workflow efficiency and diagnostic confidence in breast cancer detection. The integration of ProFound AI into RamSoft's cloud-based RIS/PACS platform will serve over 750 sites worldwide.
iCAD also partnered with Windsong Radiology to implement AI-Powered Mammography. This strategic commercial agreement will champion the first wave of ProFound AI Breast Health Suite expansion.
Related reading: Spacex Rocket Fails to Deliver Starlink Satellites to Correct Orbit
Partnership to Deliver Solutions Across North America
iCAD and RamSoft have announced a partnership to deliver ProFound AI-Powered Mammography Solutions across North America. This strategic commercial preferred distributor and integration partnership aims to enhance workflow efficiency and diagnostic confidence in breast cancer detection.
The partnership will integrate iCAD's ProFound AI Breast Health Suite into RamSoft's cloud-based RIS/PACS platform, serving over 750 sites worldwide. This integration will be available through RamSoft's PowerServer platform, which is FDA 510(k) cleared and IHE mammo profile compliant.
The ProFound AI technology addresses the challenge of 20-40% of breast cancers remaining undetected by traditional screening mammography. This highlights the need for advanced solutions in breast cancer detection.
The system features customizable layouts, MG CAD Markers support, and digital breast tomosynthesis (DBT) capabilities, streamlining workflow and improving diagnostic efficiency.
Alibaba Cloud Expands Executive Leadership
Alibaba Cloud has made a significant move by expanding its executive leadership team. Mark Koeniguer, a seasoned executive with over 30 years of experience in MedTech, AI, and digital health, has joined the team.
Koeniguer brings a wealth of experience to the table, having previously held executive roles at companies like Riverain Technologies, Volpara Health, R2 Technology, Stereotaxis, and GE Healthcare. His impressive track record includes a 400% increase in annual recurring revenue and the launch of two FDA-cleared products at his previous company, ScreenPoint Medical.
In his new role, Koeniguer will focus on revenue growth across North America and globally, leveraging his expertise in the medical imaging field and software as a medical device (SaMD) space.
On a similar theme: Experience Modifier
Industry Events
iCAD, Inc. regularly participates in industry conferences to stay at the forefront of medical advancements. One notable event is the MedInvest MedTech, AI & Digital Health Conference.
iCAD's leadership has been recognized for its contributions to AI-powered breast health solutions. This expertise was on display at the MedInvest MedTech, AI & Digital Health Conference.
15th Annual Craig-Hallum Alpha Select Conference
The 15th Annual Craig-Hallum Alpha Select Conference was a notable event. iCAD, Inc. was set to attend this conference.
Nashua, New Hampshire, was the location of the conference. iCAD, Inc. is based in Nashua, New Hampshire.
iCAD, Inc. has a mission to create a world where cancer can't hide. This mission is a driving force behind the company's work.
iCAD, Inc. is a global leader in its field. The company's presence at the conference highlights its commitment to innovation and progress.
On a similar theme: Paytm Mission
Participate in MedInvest Conference
iCAD will participate in the MedInvest MedTech, AI & Digital Health Conference.

The conference is scheduled to take place in the future, with a specific date mentioned as June 04, 2024.
iCAD is a global leader with a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions.
The company is listed on the NASDAQ stock exchange with the ticker symbol ICAD.
Executive Leadership
ICAD Inc. has made a significant move in expanding its executive leadership with the appointment of Mark Koeniguer as Chief Commercial Officer.
Mark Koeniguer brings over 30 years of experience in MedTech, AI, and digital health to his new role.
He has a proven track record of success, having achieved a 400% increase in annual recurring revenue in his previous position as CEO of ScreenPoint Medical.
Koeniguer's extensive experience in the medical imaging field and software as a medical device (SaMD) space will be invaluable in driving revenue growth for ICAD.
In his new role, Koeniguer will oversee commercial sales teams, partnerships, operations, and customer success globally.
See what others are reading: Review of the Role and Effectiveness of Non-executive Directors
AI-Powered Solutions
ICAD Inc. has partnered with RamSoft to deliver ProFound AI-Powered Mammography Solutions across North America.
This collaboration aims to enhance workflow efficiency and diagnostic confidence in breast cancer detection, addressing the challenge of 20-40% of breast cancers remaining undetected by traditional screening mammography.
The integrated solution will be available through RamSoft's PowerServer platform, which is FDA 510(k) cleared and IHE mammo profile compliant. This platform features customizable layouts, MG CAD Markers support, and digital breast tomosynthesis (DBT) capabilities, streamlining workflow and improving diagnostic efficiency.
Mammolink will be the first organization to implement the integrated solution, leveraging iCAD's ProFound AI technology to improve breast cancer detection.
Here's an interesting read: Ecommerce Software Solution Development
Frequently Asked Questions
Is iCAD a good stock to buy?
iCAD, Inc. is considered a neutral investment opportunity by one stock analyst, with a "Hold" rating indicating it may perform similarly to the overall market. Further research is recommended to determine if iCAD is a good fit for your investment portfolio.
What does the iCAD company do?
iCAD Inc. is a medical-device manufacturer that develops computer-aided detection (CAD) technology to help diagnose breast, prostate, and colorectal cancers. Their technology also supports radiation therapy treatment.
Why is iCAD stock dropping?
iCAD stock is dropping due to uncertainty in revenue forecasts, which is affecting its Price-to-Sales (P/S) ratio. This inconsistency is causing investors to reevaluate the company's stock performance.
Featured Images: pexels.com


